Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

OriC321

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Zhejiang University

Drug class:

BCMA-targeted CAR-T immunotherapy, GPRC5D-targeted CAR-T immunotherapy

Related drugs:

‹

idecabtagene vicleucel (2)

ciltacabtagene autoleucel (2)

equecabtagene autoleucel (1)

Autologous CAR-T cells (0)

BCMA CAR-T cell therapy (0)

BCMA targeted CAR T (0)

BCMA targeted CAR T-cells (0)

BCMA-BCL2L1-CART (0)

BCMA-PD1-CART Cells (0)

CART-138/BCMA/19/more (0)

CART-BCMA/CS1 (0)

CD19/BCMA targeted CAR T-cells (0)

Descartes-08 (0)

FHVH-BCMA-T (0)

MDC-CAR-BCMA001 (0)

CART-ddBCMA (0)

anti-BCMA CAR-T cells (0)

multi-target gene-modified CAR-T/TCR-T cell immunotherapy (0)

›